Trial Profile
A Randomized, Open-Label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Ganciclovir (Primary) ; Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
- Focus Therapeutic Use
- Acronyms VICTOR
- Sponsors Roche
- 16 Feb 2016 Results published in the Clinical Infectious Diseases
- 01 May 2009 Long-term results have been published in the American Journal of Transplantation.
- 01 Sep 2007 Status changed from in progress to completed.